Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

TLDR

Myelodysplastic syndromes are heterogeneous myeloid disorders with variable courses, and diagnostic criteria are evolving to better stratify patients using morphology, cytogenetics, and cytopenias. The guidelines aim to improve patient classification to guide treatment by addressing diagnostic classification, molecular abnormalities, therapeutic options, and recommended approaches. The guidelines outline treatment strategies including supportive care, anemia management, low‑ and high‑intensity therapies, and detailed recommendations for diagnostic classification and therapeutic options.

Abstract

The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the presence of cytopenias. More accurate classification of patients will allow for better treatment guidance. Treatment encompasses supportive care, treatment of anemia, low-intensity therapy, and high-intensity therapy. This portion of the guidelines focuses on diagnostic classification, molecular abnormalities, therapeutic options, and recommended treatment approaches.